Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment
Open Access
- 22 December 2020
- journal article
- Published by SciRes Literature LLC in Journal of Biomedical Research & Environmental Sciences
- Vol. 1 (8), 431-438
- https://doi.org/10.37871/jbres1175
Abstract
Potential clinical benefit in SARS-CoV-2 with remdesivir have been noticed. Recently, FDA has granted the use of remdesivir for COVID-therapy. However, the efficacy of remdesivir alone or with combination of other antivirals, like chloroquine or hydroxychloroquine is still questionable, especially in terms of benefits vs. risk ratio. We here did a search for relevant pharmacological evidences with regards to the Pharmacokinetics (PK) and Pharmacodynamics (PD) of appropriate antiviral compounds against COVID-19 alone or in combination with other potential therapies. Drug–Drug Interactions (DDIs), if any in case of combo treatment have also been taken into consideration. We found promising in vitro evidence for using remdesivir, in combination with (hydroxy) chloroquine and/or favipiravir against SARS-CoV-2. However, clinical trial results are not that satisfactory as expected and limit the use in practice. Additionally, some other drug combination with remdesivir have been proposed in this article for future improvement in therapies.Keywords
This publication has 45 references indexed in Scilit:
- Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirusJournal of Infection, 2013
- Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing StrategiesAntimicrobial Agents and Chemotherapy, 2011
- A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic studyAnalytical and Bioanalytical Chemistry, 2008
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compoundsJournal of Clinical Virology, 2004
- HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirusBiochemical and Biophysical Research Communications, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Effects of chloroquine on viral infections: an old drug against today's diseasesThe Lancet Infectious Diseases, 2003
- Metabolic fate of14C-camostat mesylate in man, rat and dog after intravenous administrationXenobiotica, 1994
- Dose refinements in long-term therapy of rheumatoid arthritis with antimalarialsThe American Journal of Medicine, 1983